{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:31Z","timestamp":1793405311060,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xuzhou Basic Research Program","award":["KC23067"],"award-info":[{"award-number":["KC23067"]}]},{"name":"the Scientific Foundation for Talented Scholars of Xuzhou Medical University","award":["D2021070"],"award-info":[{"award-number":["D2021070"]}]},{"name":"the Scientific Foundation for Talented Scholars of Xuzhou Medical University","award":["D2021067"],"award-info":[{"award-number":["D2021067"]}]},{"DOI":"10.13039\/100015612","name":"CancerFree KIDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NS28840"],"award-info":[{"award-number":["NS28840"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82103237"],"award-info":[{"award-number":["82103237"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Innovation Foundation of Xuzhou Municipal Health Commission","award":["XWKYHT20240119"],"award-info":[{"award-number":["XWKYHT20240119"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In neurofibromatosis type 1 (NF1), loss-of-function mutations in the\n                    <jats:italic>NF1<\/jats:italic>\n                    gene increase activation of the RAS\u2013MEK\u2013ERK signaling cascade, driving tumorigenesis. MEK inhibitors (MEKi) inhibit tumor growth and significantly shrink nerve tumors (neurofibromas). However, MEKi treatment alone fails to eradicate tumor cells, and tumor regrowth occurs after drug withdrawal, highlighting the limitations of targeting the single MEK pathway. An alternative strategy is to promote dephosphorylation of hyperactive kinases that drive tumor growth by enhancing phosphatase activity. We identified deregulated expression of genes encoding subunits of the PP2A phosphatase in neurofibroma and neurofibroma Schwann cells. We confirmed significant reductions in both the expression and enzymatic activity of the PP2A A and C subunits. FTY720, a compound known to restore PP2A phosphatase activity, inhibited tumor sphere formation by mouse and human neurofibroma Schwann cell progenitor cells, suppressed the proliferation of both primary and immortalized neurofibroma-derived Schwann cells, and induced cell apoptosis in vitro. Furthermore, treatment with FTY720\u2014alone or in combination with MEKi\u2014significantly suppressed tumor number and reduced tumor burden in remaining tumors in a murine model of NF1, highlighting the promise of using FTY720 as a novel therapeutic strategy in NF1.\n                  <\/jats:p>","DOI":"10.1186\/s40478-026-02315-w","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:53:14Z","timestamp":1778529194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma"],"prefix":"10.1186","volume":"14","author":[{"given":"Minghui","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Pundavela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2315_CR1","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH et al (2017) Neurofibromatosis type 1. Nat Rev Dis Primers 3:17004","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"2315_CR2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/ddp212","volume":"18","author":"A Sabbagh","year":"2009","unstructured":"Sabbagh A et al (2009) Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet 18(15):2768\u20132778","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2315_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG et al (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A(2):327\u2013332","journal-title":"Am J Med Genet A"},{"issue":"11","key":"2315_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.trecan.2018.09.002","volume":"4","author":"J Taeubner","year":"2018","unstructured":"Taeubner J et al (2018) Penetrance and expressivity in inherited cancer predisposing syndromes. Trends Cancer 4(11):718\u2013728","journal-title":"Trends Cancer"},{"issue":"1","key":"2315_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","volume":"151","author":"SA Rasmussen","year":"2000","unstructured":"Rasmussen SA, Friedman JM (2000) NF1 gene and neurofibromatosis 1. Am J Epidemiol 151(1):33\u201340","journal-title":"Am J Epidemiol"},{"issue":"39","key":"2315_CR6","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1038\/s41388-021-01979-z","volume":"40","author":"C Jiang","year":"2021","unstructured":"Jiang C, McKay RM, Le LQ (2021) Tumorigenesis in neurofibromatosis type 1: role of the microenvironment. Oncogene 40(39):5781\u20135787","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"2315_CR7","doi-asserted-by":"publisher","first-page":"i23","DOI":"10.1093\/noajnl\/vdz045","volume":"2","author":"JS Fletcher","year":"2020","unstructured":"Fletcher JS, Pundavela J, Ratner N (2020) After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neuro-Oncol Adv 2(Suppl 1):i23\u2013i32","journal-title":"Neuro-Oncol Adv"},{"issue":"4","key":"2315_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s13402-025-01054-9","volume":"48","author":"Y Yu","year":"2025","unstructured":"Yu Y et al (2025) From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors. Cell Oncol (Dordr) 48(4):841\u2013857","journal-title":"Cell Oncol (Dordr)"},{"issue":"17","key":"2315_CR9","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41388-022-02290-1","volume":"41","author":"BN Somatilaka","year":"2022","unstructured":"Somatilaka BN et al (2022) Malignant peripheral nerve sheath tumor: models, biology, and translation. Oncogene 41(17):2405\u20132421","journal-title":"Oncogene"},{"issue":"4","key":"2315_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","volume":"63","author":"R Ballester","year":"1990","unstructured":"Ballester R et al (1990) The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63(4):851\u2013859","journal-title":"Cell"},{"issue":"5","key":"2315_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner N, Miller SJ (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15(5):290\u2013301","journal-title":"Nat Rev Cancer"},{"key":"2315_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/B978-0-444-64076-5.00051-X","volume":"148","author":"PJ Cimino","year":"2018","unstructured":"Cimino PJ, Gutmann DH (2018) Neurofibromatosis type 1. Handb Clin Neurol 148:799\u2013811","journal-title":"Handb Clin Neurol"},{"issue":"7","key":"2315_CR13","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","volume":"65","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta B et al (2005) Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 65(7):2755\u20132760","journal-title":"Cancer Res"},{"key":"2315_CR14","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049362","author":"C Anastasaki","year":"2022","unstructured":"Anastasaki C, Orozco P, Gutmann DH (2022) RAS and beyond: the many faces of the Neurofibromatosis type 1 protein. Dis Model Mech. https:\/\/doi.org\/10.1242\/dmm.049362","journal-title":"Dis Model Mech"},{"issue":"29","key":"2315_CR15","doi-asserted-by":"publisher","first-page":"9948","DOI":"10.1074\/jbc.RA119.010981","volume":"295","author":"JA Mund","year":"2020","unstructured":"Mund JA et al (2020) Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1. J Biol Chem 295(29):9948\u20139958","journal-title":"J Biol Chem"},{"issue":"1","key":"2315_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ et al (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123(1):340\u2013347","journal-title":"J Clin Invest"},{"issue":"11","key":"2315_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","volume":"24","author":"PMK de Blank","year":"2022","unstructured":"de Blank PMK et al (2022) MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. Neuro Oncol 24(11):1845\u20131856","journal-title":"Neuro Oncol"},{"issue":"26","key":"2315_CR18","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E et al (2016) Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375(26):2550\u20132560","journal-title":"N Engl J Med"},{"issue":"10","key":"2315_CR19","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"AM Gross","year":"2023","unstructured":"Gross AM et al (2023) Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro Oncol 25(10):1883\u20131894","journal-title":"Neuro Oncol"},{"key":"2315_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1645868","volume":"14","author":"C Zhang","year":"2026","unstructured":"Zhang C et al (2026) Phosphatases in tumor cell immune escape: a perspective based on the camouflage, coercion, cytoprotection. Front Cell Dev Biol 14:1645868","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2315_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13046-025-03560-y","volume":"44","author":"F Sarais","year":"2025","unstructured":"Sarais F et al (2025) Targeting PP2A in cancer: an underrated option. J Exp Clin Cancer Res 44(1):295","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"2315_CR22","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.1016\/S0021-9258(18)53179-3","volume":"268","author":"P Hendrix","year":"1993","unstructured":"Hendrix P et al (1993) Analysis of subunit isoforms in protein phosphatase 2A holoenzymes from rabbit and Xenopus. J Biol Chem 268(10):7330\u20137337","journal-title":"J Biol Chem"},{"key":"2315_CR23","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.248187","author":"P Sandal","year":"2021","unstructured":"Sandal P et al (2021) Protein phosphatase 2A - structure, function and role in neurodevelopmental disorders. J Cell Sci. https:\/\/doi.org\/10.1242\/jcs.248187","journal-title":"J Cell Sci"},{"issue":"2","key":"2315_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/cancers7020648","volume":"7","author":"M Kiely","year":"2015","unstructured":"Kiely M, Kiely PA (2015) PP2A: the wolf in sheep\u2019s clothing? Cancers (Basel) 7(2):648\u2013669","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2315_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00401-019-02086-w","volume":"139","author":"Y Yu","year":"2020","unstructured":"Yu Y et al (2020) NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathol 139(1):157\u2013174","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2315_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","volume":"130","author":"MR Junttila","year":"2007","unstructured":"Junttila MR et al (2007) CIP2A inhibits PP2A in human malignancies. Cell 130(1):51\u201362","journal-title":"Cell"},{"issue":"3","key":"2315_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","volume":"115","author":"I Cristobal","year":"2010","unstructured":"Cristobal I et al (2010) SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 115(3):615\u2013625","journal-title":"Blood"},{"issue":"9","key":"2315_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/sj.onc.1203389","volume":"19","author":"GA Calin","year":"2000","unstructured":"Calin GA et al (2000) Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 19(9):1191\u20131195","journal-title":"Oncogene"},{"issue":"1","key":"2315_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1042\/bj2560283","volume":"256","author":"C Bialojan","year":"1988","unstructured":"Bialojan C, Takai A (1988) Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 256(1):283\u2013290","journal-title":"Biochem J"},{"issue":"6","key":"2315_CR30","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1073\/pnas.85.6.1768","volume":"85","author":"M Suganuma","year":"1988","unstructured":"Suganuma M et al (1988) Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci U S A 85(6):1768\u20131771","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2315_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2013.02.036","volume":"335","author":"P Seshacharyulu","year":"2013","unstructured":"Seshacharyulu P et al (2013) Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 335(1):9\u201318","journal-title":"Cancer Lett"},{"issue":"52","key":"2315_CR32","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.1038\/sj.onc.1209038","volume":"24","author":"JD Arroyo","year":"2005","unstructured":"Arroyo JD, Hahn WC (2005) Involvement of PP2A in viral and cellular transformation. Oncogene 24(52):7746\u20137755","journal-title":"Oncogene"},{"key":"2315_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108834","volume":"269","author":"DA Neale","year":"2025","unstructured":"Neale DA et al (2025) Understanding the regulatory landscape of protein phosphatase 2A (PP2A): pharmacological modulators and potential therapeutics. Pharmacol Ther 269:108834","journal-title":"Pharmacol Ther"},{"key":"2315_CR34","doi-asserted-by":"publisher","first-page":"37297","DOI":"10.1038\/srep37297","volume":"6","author":"MM Rahman","year":"2016","unstructured":"Rahman MM et al (2016) The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells. Sci Rep 6:37297","journal-title":"Sci Rep"},{"issue":"11","key":"2315_CR35","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","volume":"122","author":"JJ Oaks","year":"2013","unstructured":"Oaks JJ et al (2013) Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 122(11):1923\u20131934","journal-title":"Blood"},{"issue":"4","key":"2315_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1535-7163.MCT-13-0150","volume":"13","author":"I Cristobal","year":"2014","unstructured":"Cristobal I et al (2014) PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 13(4):938\u2013947","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2315_CR37","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s00432-018-2765-7","volume":"144","author":"H Fujiki","year":"2018","unstructured":"Fujiki H et al (2018) The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers. J Cancer Res Clin Oncol 144(12):2339\u20132349","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2315_CR38","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jcb.24003","volume":"113","author":"Y Yang","year":"2012","unstructured":"Yang Y et al (2012) Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem 113(4):1314\u20131322","journal-title":"J Cell Biochem"},{"issue":"48","key":"2315_CR39","doi-asserted-by":"publisher","first-page":"47408","DOI":"10.1074\/jbc.M307687200","volume":"278","author":"A Billich","year":"2003","unstructured":"Billich A et al (2003) Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278(48):47408\u201347415","journal-title":"J Biol Chem"},{"issue":"6972","key":"2315_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"M Matloubian","year":"2004","unstructured":"Matloubian M et al (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355\u2013360","journal-title":"Nature"},{"issue":"3","key":"2315_CR41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.pharmthera.2005.05.002","volume":"108","author":"K Chiba","year":"2005","unstructured":"Chiba K (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 108(3):308\u2013319","journal-title":"Pharmacol Ther"},{"issue":"42","key":"2315_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado6342","volume":"10","author":"J Pundavela","year":"2024","unstructured":"Pundavela J et al (2024) Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive Neurofibromatosis type 1 nerve tumor initiation and maintenance. Sci Adv 10(42):eado6342","journal-title":"Sci Adv"},{"issue":"6","key":"2315_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.stem.2008.10.003","volume":"3","author":"JP Williams","year":"2008","unstructured":"Williams JP et al (2008) Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell 3(6):658\u2013669","journal-title":"Cell Stem Cell"},{"issue":"10","key":"2315_CR44","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","volume":"96","author":"H Li","year":"2016","unstructured":"Li H et al (2016) Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab Invest 96(10):1105\u20131115","journal-title":"Lab Invest"},{"issue":"8","key":"2315_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110528","volume":"27","author":"A Giovenzana","year":"2024","unstructured":"Giovenzana A et al (2024) T cell trafficking in human chronic inflammatory diseases. iScience 27(8):110528","journal-title":"iScience"},{"issue":"13-14","key":"2315_CR46","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.intimp.2006.07.030","volume":"6","author":"M Hofmann","year":"2006","unstructured":"Hofmann M, Brinkmann V, Zerwes HG (2006) FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 6(13\u201314):1902\u20131910","journal-title":"Int Immunopharmacol"},{"issue":"50","key":"2315_CR47","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1038\/s41388-023-02840-1","volume":"42","author":"A Di Mambro","year":"2023","unstructured":"Di Mambro A et al (2023) SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML. Oncogene 42(50):3670\u20133683","journal-title":"Oncogene"},{"issue":"8","key":"2315_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102248","volume":"298","author":"JM Sontag","year":"2022","unstructured":"Sontag JM et al (2022) A new paradigm for regulation of protein phosphatase 2A function via Src and Fyn kinase-mediated tyrosine phosphorylation. J Biol Chem 298(8):102248","journal-title":"J Biol Chem"},{"issue":"41","key":"2315_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404926","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang Y et al (2024) Unraveling the CDK9\/PP2A\/ERK network in transcriptional pause release and complement activation in KRAS-mutant cancers. Adv Sci 11(41):e2404926","journal-title":"Adv Sci"},{"issue":"2","key":"2315_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41419-024-06501-3","volume":"15","author":"Y Ma","year":"2024","unstructured":"Ma Y et al (2024) CUL4B mutations impair human cortical neurogenesis through PP2A-dependent inhibition of AKT and ERK. Cell Death Dis 15(2):121","journal-title":"Cell Death Dis"},{"issue":"4","key":"2315_CR51","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1158\/1535-7163.MCT-20-0663","volume":"20","author":"M Scarpa","year":"2021","unstructured":"Scarpa M et al (2021) PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3beta-mediated c-Myc and Pim-1 proteasomal degradation. Mol Cancer Ther 20(4):676\u2013690","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2315_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12964-024-01536-7","volume":"22","author":"G Nadel","year":"2024","unstructured":"Nadel G et al (2024) Phosphorylation of PP2Ac by PKC is a key regulatory step in the PP2A-switch-dependent AKT dephosphorylation that leads to apoptosis. Cell Commun Signal 22(1):154","journal-title":"Cell Commun Signal"},{"issue":"25","key":"2315_CR53","doi-asserted-by":"publisher","first-page":"22847","DOI":"10.1074\/jbc.M201830200","volume":"277","author":"PP Ruvolo","year":"2002","unstructured":"Ruvolo PP et al (2002) A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 277(25):22847\u201322852","journal-title":"J Biol Chem"},{"issue":"3","key":"2315_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1349-7006.2004.tb02214.x","volume":"95","author":"S Simizu","year":"2004","unstructured":"Simizu S, Tamura Y, Osada H (2004) Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance. Cancer Sci 95(3):266\u2013270","journal-title":"Cancer Sci"},{"key":"2315_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-204","volume":"9","author":"AK Ajay","year":"2010","unstructured":"Ajay AK et al (2010) Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest\/apoptosis and inhibits tumor progression. Mol Cancer 9:204","journal-title":"Mol Cancer"},{"issue":"52","key":"2315_CR56","doi-asserted-by":"publisher","first-page":"42644","DOI":"10.1074\/jbc.M502464200","volume":"280","author":"DG Adams","year":"2005","unstructured":"Adams DG et al (2005) Positive regulation of Raf1-MEK1\/2-ERK1\/2 signaling by protein serine\/threonine phosphatase 2A holoenzymes. J Biol Chem 280(52):42644\u201342654","journal-title":"J Biol Chem"},{"issue":"20","key":"2315_CR57","doi-asserted-by":"publisher","first-page":"15076","DOI":"10.1074\/jbc.M109.078915","volume":"285","author":"GK Kilili","year":"2010","unstructured":"Kilili GK, Kyriakis JM (2010) Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1\/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem 285(20):15076\u201315087","journal-title":"J Biol Chem"},{"issue":"13","key":"2315_CR58","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1158\/1078-0432.CCR-18-3224","volume":"25","author":"A Ramkissoon","year":"2019","unstructured":"Ramkissoon A et al (2019) Targeted inhibition of the dual specificity phosphatases DUSP1 and DUSP6 suppress MPNST growth via JNK. Clin Cancer Res 25(13):4117\u20134127","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2315_CR59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","volume":"45","author":"R Piazza","year":"2013","unstructured":"Piazza R et al (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45(1):18\u201324","journal-title":"Nat Genet"},{"key":"2315_CR60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ebiom.2016.06.007","volume":"9","author":"AV Patel","year":"2016","unstructured":"Patel AV et al (2016) An ShRNA screen identifies MEIS1 as a driver of malignant peripheral nerve sheath tumors. EBioMedicine 9:110\u2013119","journal-title":"EBioMedicine"},{"issue":"5","key":"2315_CR61","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41388-020-01581-9","volume":"40","author":"Y Na","year":"2021","unstructured":"Na Y et al (2021) MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene 40(5):951\u2013963","journal-title":"Oncogene"},{"issue":"3","key":"2315_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/0961203314552117","volume":"24","author":"YA Lashine","year":"2015","unstructured":"Lashine YA et al (2015) Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus 24(3):240\u2013247","journal-title":"Lupus"},{"issue":"1","key":"2315_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1878-5085-5-3","volume":"5","author":"S Baldacchino","year":"2014","unstructured":"Baldacchino S et al (2014) Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. EPMA J 5(1):3","journal-title":"EPMA J"},{"key":"2315_CR64","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biocel.2017.10.002","volume":"96","author":"B Meeusen","year":"2018","unstructured":"Meeusen B, Janssens V (2018) Tumor suppressive protein phosphatases in human cancer: emerging targets for therapeutic intervention and tumor stratification. Int J Biochem Cell Biol 96:98\u2013134","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"2315_CR65","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.7150\/ijbs.107130","volume":"21","author":"T Yu","year":"2025","unstructured":"Yu T et al (2025) E3 ligase MKRN2 destabilizes PPP2CA proteins to inactivate canonical Wnt pathway and mitigates tumorigenesis of clear cell renal cell carcinoma. Int J Biol Sci 21(12):5361\u20135377","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2315_CR66","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.mce.2013.09.033","volume":"382","author":"WJ McDonald","year":"2014","unstructured":"McDonald WJ et al (2014) Progestin-inducible EDD E3 ubiquitin ligase binds to alpha4 phosphoprotein to regulate ubiquitination and degradation of protein phosphatase PP2Ac. Mol Cell Endocrinol 382(1):254\u2013261","journal-title":"Mol Cell Endocrinol"},{"key":"2315_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2017.01.001","volume":"135","author":"G Semenova","year":"2017","unstructured":"Semenova G et al (2017) Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1. Biochimie 135:1\u20135","journal-title":"Biochimie"},{"issue":"1","key":"2315_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.70012","volume":"52","author":"S Pournajaf","year":"2025","unstructured":"Pournajaf S et al (2025) Fingolimod inhibits C6 rat glioma proliferation and migration, induces Sub-G1 cell cycle arrest, mitochondrial and extrinsic apoptosis in vitro and reduces tumour growth in vivo. Clin Exp Pharmacol Physiol 52(1):e70012","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"2315_CR69","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.3390\/md13063276","volume":"13","author":"I Cristobal","year":"2015","unstructured":"Cristobal I et al (2015) Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer. Mar Drugs 13(6):3276\u20133286","journal-title":"Mar Drugs"},{"issue":"6","key":"2315_CR70","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1541-7786.MCR-13-0542","volume":"12","author":"AS Farrell","year":"2014","unstructured":"Farrell AS et al (2014) Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res 12(6):924\u2013939","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2315_CR71","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","volume":"23","author":"J Liang","year":"2013","unstructured":"Liang J et al (2013) Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23(1):107\u2013120","journal-title":"Cancer Cell"},{"issue":"11","key":"2315_CR72","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.4049\/jimmunol.164.11.5761","volume":"164","author":"DD Pinschewer","year":"2000","unstructured":"Pinschewer DD et al (2000) FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 164(11):5761\u20135770","journal-title":"J Immunol"},{"issue":"5","key":"2315_CR73","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41571-020-0361-7","volume":"17","author":"D Killock","year":"2020","unstructured":"Killock D (2020) Selumetinib benefits children with inoperable plexiform neurofibromas. Nat Rev Clin Oncol 17(5):273","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2315_CR74","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood.2020010344","volume":"139","author":"S Goswami","year":"2022","unstructured":"Goswami S et al (2022) PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc\/p21 axis in human and murine acute myeloid leukemia. Blood 139(9):1340\u20131358","journal-title":"Blood"},{"issue":"11\u201312","key":"2315_CR75","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10495-019-01570-8","volume":"24","author":"Y Xiong","year":"2019","unstructured":"Xiong Y et al (2019) PP2Ac upregulates PI3K-Akt signaling and induces hepatocyte apoptosis in liver donor after brain death. Apoptosis 24(11\u201312):921\u2013933","journal-title":"Apoptosis"},{"issue":"6","key":"2315_CR76","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s11912-024-01527-4","volume":"26","author":"B Na","year":"2024","unstructured":"Na B, Shah SR, Vasudevan HN (2024) Past, present, and future therapeutic strategies for NF-1-associated tumors. Curr Oncol Rep 26(6):706\u2013713","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"2315_CR77","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke AB et al (2012) MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72(13):3228\u20133237","journal-title":"Cancer Res"},{"issue":"6","key":"2315_CR78","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.4049\/jimmunol.165.6.3250","volume":"165","author":"Y Nagahara","year":"2000","unstructured":"Nagahara Y, Ikekita M, Shinomiya T (2000) Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol 165(6):3250\u20133259","journal-title":"J Immunol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02315-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02315-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02315-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:35:29Z","timestamp":1784039729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02315-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02315-w","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis of human tissue samples was approved by the institutional review board of Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine (SH9H-2019-T163-2, SH9H-2019-T163-5). All procedures related to animal housing and experimentation were reviewed and approved by the Intuitional Animal Care and Use Committee at Cincinnati Children\u2019s Hospital Medical Center and Xuzhou Medical University (Approval No.202303T017), in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals (NIH Pub. No.85-23, revised 1996).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"During the preparation of this work the author used Deepseek in order to do the English Revision. After using this tool\/service, the author reviewed and edited the content as needed and takes full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI"}}],"article-number":"147"}}